Review of myomectomy  by Horng, Huann-Cheng et al.
Available online at www.sciencedirect.comTaiwanese Journal of Obstetrics & Gynecology 51 (2012) 7e11
www.tjog-online.comReview Article
Review of myomectomy
Huann-Cheng Horng a,b, Kuo-Chang Wen a,b, Wen-Hsiang Su c,d, Chien-Sheng Chen d,**,
Peng-Hui Wang a,b,*
aDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan
bDepartment of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan
cDepartment of Laboratory Medicine, Yee-Zen Hospital, Tao-Yuan, Taiwan
d Institute of Systems Biology and Bioinformatics, and Institute of Statistics, National Central University, Tao-Yuan, Taiwan
Accepted 11 January 2012AbstractUterine fibroids (also called leiomyomas or myomas) are the most common disorder among women of reproductive age, with an incidence of
between 20% and 80%; they are often detected incidentally in routine healthy examinations, through bimanual pelvic and/or ultrasound
examination, because uterine fibroids are rarely associated with symptoms. Sometimes, uterine fibroids may be complicated by a variety of
symptoms, including menstrual disturbance (e.g., menorrhagia, dysmenorrhea, intermenstrual bleeding), pressure symptoms, bloated sensation,
increased urinary frequency, bowel disturbance, or pelvic pain; therefore definite treatment is requested. Hysterectomy may be the first choice for
women who have completed their child-birth; however, many women may prefer to keep the uterus if the uterine fibroids-related symptoms can
be appropriately controlled. Among these conservative therapies, myomectomy may be one of the most popular methods for the woman who
would like to preserve her future fertility, as the majority of symptoms can be relieved by myomectomy; this contributes to the value of this
review. This review addresses the use of myomectomy in the management of symptomatic uterine fibroids.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Uterine fibroids (also called leiomyomas or myomas) are
the most common disorder among women of reproductive age;
the incidence ranges from 20% to 80%, based on the different
evaluation tools and definitions [1,2]. Uterine fibroids are
often detected incidentally in routine healthy examinations,
even by bimanual pelvic and/or ultrasound examinations. The
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doi:10.1016/j.tjog.2012.01.003sometimes, they may cause problems. Fibroid-related symp-
toms include menstrual disturbances (e.g., menorrhagia,
dysmenorrhea, intermenstrual bleeding), pressure symptoms
(e.g., bloated sensation, increased urinary frequency, bowel
disturbance), and pelvic pain [4,5]. More rarely, uterine
fibroids may influence the reproductive functions, especially
the submucous location, with resultant subfertility, and
pregnancy-associated complications, such as early pregnancy
loss, myoma degeneration and pain, preterm labor or fetal
malpresentation [6]. If these symptoms occur, definite treat-
ment is sometimes required [7].
One of the most important definite treatments is hysterec-
tomy, which is considered when women have finished bearing
children [8]. Hysterectomy may be the second most common
reason for exploratory laparotomy in women during the
reproductive age [9]. However, psychologically, the uterus has
been regarded as the regulator and controller of importantcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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vitality, and a maintainer of youth and attractiveness [10],
resulting in a modern trend whereby women may re-consider
the possibility of organ-preservation [11]. For women who
wish to retain their childbearing potential, an organ-preserving
strategy, including expectant management [1], medical therapy
[12,13], surgical intervention [14], uterine artery embolization
[15], uterine artery ligation [16], uterine vessel occlusion or
ablative techniques [17] etc. has been the preferred treatment
[18]. However, malignant-type leiomyosarcomas should be
kept in mind if conservative treatment is planned [19].
Therefore, a distinction between benign and malignant smooth
muscle tumors should be attempted using, e.g., colored
Doppler ultrasound, magnetic resonance imaging, positron
emission tomography, or rapid growth of the tumor itself;
unfortunately, none of these are sensitive or specific enough
[20,21]. All contribute to the delayed diagnosis of the majority
of leiomyosarcomas. In fact, they are frequently diagnosed
after hysterectomy or myomectomy, at the time of the path-
ologic review [22]. Fortunately, the incidence of leiomyo-
sarcoma is extremely rare [23]. In addition, the question of
what should to do for women with symptomatic uterine
fibroids who wish to preserve their uterus, is raised. In past
years, the method of management of myomas has developed
dramatically, and multidisciplinary approach is frequently
used. Frequently, relatively less invasive procedures are
designed to retain the uterus, with or without concern for
future fertility [24]. Therefore, it is not easy to give an answer
to this question, because each method has its own strengths
and weaknesses [25,26]. In addition, some patients are treated
with one of the therapies alone [6e17,23,25,26], while others
are treated with combination therapy [9,18], which contains
more than one of the methods [24].
The choice of fibroid treatment is dependent on the
patient’s age and preference, the reason for treatment, and the
issue of fertility preservation [27], which results in individu-
alization of selection of therapy. Although this may be
reasonable, it may not be practicable, since the question “how
should we treat women with symptomatic uterine fibroids who
want uterine preservation?” is still unanswered. The following
can make it easier to understanddif subsequent fertility is
desired, myomectomy remains the standard of care for women
with symptomatic fibroids seeking fertility preservation
[28,29]. Therefore, the focus of this review is limited to dis-
cussing the use of myomectomy in the management of
symptomatic uterine fibroids.
Conventional laparotomy for myomectomy (CLT-M)
As shown above, myomectomy may be one of the best
choices in the management of young women who have
a desire to retain their potential for future fertility. In the
beginning of the 19th century, Bonney advocated myomec-
tomy in the restoration and preservation of physiological
function of the uterus and a higher surgical ideal than
hysterectomy [30]; this was supported by many case-
controlled studies. A retrospective study compared themorbidity between total hysterectomy and myomectomy and
concluded that myomectomy was associated with less risk of
intraoperative visceral injuries and infection than total
hysterectomy [31]. Another study showed significantly less
estimated blood loss in the myomectomy group than in the
total hysterectomy group, although there was a longer opera-
tive time in the myomectomy group [32]. These authors all
concluded that myomectomy is a safe and alternative proce-
dure to abdominal hysterectomy [31,32].
Large fibroids can be completely and successfully removed
through conventional laparotomy for myomectomy (CLT-M),
or even during cesarean section [33]. During CLT-M, an
average skin incision of > 10 cm is made in the midline or
Pfannenstiel direction [34,35]. The main advantage of CLT-M
is adequate operative field exposure, which results in careful
and thorough inspection and palpation of the whole uterus and
fibroids and the entire myomectomy, not only for removal of
fibroids but also for repair of the defect, can be easily per-
formed. Favorable outcomes of CLT-M for the management of
large uterine fibroids have been reported, and CLT-M can be
used in the management of up to a 36 gestation-week size
fibroid, with a weight of up to 2467 g, with acceptable oper-
ative times and estimated blood loss, and without conversion
to hysterectomy [36].
Minilaparotomy for myomectomy (MLT-M)
Minilaparotomy (MLT) has recently been identified as
another minimally invasive alternative to CLT. Similar to CLT,
the incision can be made either through the midline or in the
Pfannenstiel direction, although the Pfannenstiel approach is
more popular, mainly based on cosmetic reasons. During
MLT-M, a small suprapubic skin incision, ranging from 4 to
9 cm is made [37].
In a study which evaluated 78 women with various kinds of
benign gynecological diseases, MLT was successfully per-
formed in the majority of patients (96%); LTwas performed in
only 3 cases (4%), due to more obesity, isthmic leiomyomas,
and pelvic adhesion [37]. Cagnacci et al studied the outcome
of myomectomy by CLT, MLT and laparoscopically assisted
minilaparotomy (LA-MLT), and found that MLT-M was the
best choice; it had a similar efficacy to that of the early
outcome with LA-MLT-M, a greater efficacy than that
following CLT, and a shorter operative time than CLT-M and
LA-MLT-M [38].
In a randomized, controlled study involving 99 women, the
duration of surgery, postoperative hospital stay, and costs were
significantly lower in the MLT-M versus the CLT-M group
[39]. Since the immediate postoperative recovery was
acceptable in women who underwent MLT-M, the MLT-M
was attempted in an ambulatory setting [40,41].
Glasser studied 139 women undergoing MLT-M, and
reported advantages such as improved uterine repair, ability to
palpate the uterus, reduced operating time, same-day
discharge, and rapid return to normal activity [40]. Thomas
et al further confirmed that MLT-M is a safe, cost-effective
treatment of most symptomatic uterine fibroids in an
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fully on the same day, following 3.5 hours of recovery time
[41]. MLT-M fulfills the criteria of minimally invasive surgery,
as it is more cost-effective and does not compromise the
postoperative recovery of patients, compared with laparo-
scopic myomectomy (LM) [42].
Laparoscopic myomectomy (LM)
Although both CLT and MLT can be applied to nearly all
women with uterine fibroids who need a myomectomy proce-
dure, cosmetic consideration and postoperative recovery is
always a concern, which results in the request of minimally
invasive procedures [34,35,43]. Following the initial application
of laparoscopic myomectomy (LM) in 1979 by Semm [44], this
minimally invasive technique has become more and more
popular worldwide. Conventionally, a three- to four-port wound
technique is applied for LM. The main trocar (10 mm port) is
inserted through the umbilicus to introduce the video system
after pneumoperitoneum insufflation with carbon dioxide.
Other two- or three-accessory trocars (5mmport or 10mmport)
were inserted into the abdomen over the left lower quadrant,
right lower quadrant, and suprapubic area, for the operative
instruments and the suction irrigator machine [42].
Due to limited space during the laparoscopic procedures,
especially for larger uterine fibroids, the trocar insertion sites
sometimes need modification. For example, the Lee-Huang
point or Palmer’s point is used in the replacement of the
traditional main trocar site [45,46]. With the Lee-Huang point,
the main trocar site is moved to the midpoint between the
xiphoid process and the umbilicus (middle upper abdomen).
The accessory trocar can be made in the paramedian line
parallel to the umbilicus [46]. With a subumbilical entry,
a 1 cm vertical midline incision is made in the lower border of
the umbilicus, whereas for Palmer’s entry, a 1 cm horizontal
incision was made in the left midclavicular line, approxi-
mately 3 cm caudal to the 10th rib [45].
Myomectomy is then performed after grasp with the second
needle and injection with Pitressin into the myometrium
around the fibroids, or after finishing laparoscopic uterine
vessel occlusion [11,18,26,27,34,35,47]. Uterine fibroids are
able to be separated from the surrounding uterine muscle or
tissue by the electrocoagulation-unipolar electrode or bipolar
electrode mode [48]. Removed uterine fibroids are extracted
completely by both culdotomy (vaginal approach) [49] and
electronic morcellator (Ethicon, San Angelo, TX, USA;
abdominal approach) [50]. In conventional LM, morcellation
is performed after complete enucleation of the myoma [51]; in
modified LM, morcellation is performed while the myoma is
still attached to the uterus, i.e., in situ morcellation (ISM) [52].
ISM has been confirmed as an efficient and safe procedure for
the removal of large uterine fibroids during LM, because this
technique might be more feasible compared with conventional
morcellation, as it requires less operative time [51,52].
The myometrial edges were closed in one or two layers,
according to the depth of the uterine wound, by means of pol-
yglactin 0 sutures. If relatively inexperienced in laparoscopicsuturing, a modified suture technique, such as intracorporeal
continuous suturing, can be used as an alternative method to
finish LM successfully [53]. The use of intracorporeal suturing
is a significant component of the learning curve for LM, and
presents an even greater challengewith single incision LM [14].
In addition, some revised techniques or suture materials might
be assisted by forceps insertion and continuous interlocking
sutures using standard instruments [54].
LM has gained wide acceptance following advanced
improvement in instruments; many randomized controlled
trials have also proven the superiority of LM [55]. A recent
meta-analysis of 6 randomized controlled trials enrolled 576
women in the comparison of LM and CLT-M [56]; it was
concluded that LM has many advantages, such as less blood
loss, less of a decrease in hemoglobin, faster recovery, dimin-
ished postoperative pain, shorter hospital stay, and better
cosmetic effects, although LM seemed to require a longer
operative time compared with CLT-M. LM is technically highly
demanding and requires specialized surgical instruments,
which is not popular for the majority of gynecologists [55].
Recently, robot-assisted laparoscopy, a new technology, has
become popular in every aspect of surgery. Robotic-assisted
LM was approved by the Food and Drug Administration in
2005, and has limited advantages over conventional laparos-
copy according to the available evidence [57]. It has the
benefit of better precision and dexterity, by eliminating the
fulcrum effect experienced in conventional operative lapa-
roscopy [58]. On the contrary, longer operative times, loss of
tactile sensation necessary to detect intramural fibroids and
high costs, are negative aspects of this technology [59,60].
Ultra-minilaparotomy for myomectomy (UMLT-M)
MLT-M is a safe, cost-effective treatment of most symp-
tomatic uterine fibroids in an ambulatory setting; therefore,
MLT-M can be considered as a minimally invasive surgery
[27,34]. However, the incision wound of MLT-M is still larger
than that of LM [61,62]. To be closer to the laparoscopic wound
size and to further satisfy cosmetic requests, the incision wound
of MLT is shortened. Since the average size of an incision
wound in MLTwas about 5 cm (ranging either from 4 to 9 cm or
from 4 to 6 cm in length in different studies) [34,35,38,61], the
ultra-minilaparotomy (UMLT) wound should not extend to 4 cm
[34, 35]. The feasibility of UMLT for myomectomy (UMLT-M)
has been recently tested. Similar to CLT or MLT, the incision of
UMLT can be done either through themidline vertically, or using
the modified Pfannenstiel approach, although the incision
wound is much smaller when the UMLT-M is performed through
the midline vertical direction [34,35,43]. However, the cosmetic
effect might be better in the modified Pfannenstiel approach, as
we could hide the whole incision wound of the modified Pfan-
nenstiel approach below the pubic hair, and the transverse skin
incision parallel to the natural “Langer line” of our body tends to
heal with less scarring than the midline vertical approach [43].
A recent comprehensive review addressing the topic of the
use of UMLT for myomectomy has been published [62]. There
is more evidence supporting the advantages of UMLT-M, not
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in requiring only easy-to-perform techniques and less expen-
sive instruments in treating symptomatic women with uterine
fibroids, compared with CLT-M or LM.
The successful application of UMLT-M needs the following.
The use of small Deaver retractors (width 2.5 cm) or thyroid
retractors (width 1.5 cm) in place of the self-retaining retractor.
The small end of the abdominal retractor (width 3 cm) is barely
inserted into the wound of UMLT. The whole surgical proce-
dure, including dissection, enucleation, and suturing, must be
performed inside the abdomen through a small suprapubic
wound. In our experience, the Backhaus towel clamp (Robbins
Instruments Inc, Chatham, NJ, USA) was applied to grip the
leiomyomas towards the incision wound for removal. Larger
leiomyomas cannot be taken out with an intact shape and have to
be pared, using a “piece by piece” procedure which is like
peeling an apple. However, the size and total number of uterine
leiomyomas, and the maximum diameter of the largest, is
a crucial point for successful accomplishment of UMLT. The
final incision wound of UMLT might be extended to >4 cm
during surgery, if the total number of leiomyomas is more than
five, or the maximum diameter is >8 cm [34,35,43,62]. The
following criteria should be fulfilled in the selection of women
with uterine fibroids, such as “uncomplicated fibroids”: (1)
a number of visible uterine leiomyomas of five of less intramural
or subserous masses; (2) a maximum diameter of8 cm; (3) no
dense peritoneal adhesion or an inflammatory process; this is
a key factor for successful achievement of UMLT-M.
In conclusion, with advanced and improved technologies
and anesthesia, myomectomy might replace hysterectomy as
one of the most common procedures for women with symp-
tomatic uterine fibroids, especially for those during the
reproductive age. Although many important issues for myo-
mectomy have been extensively described in this review
article, many modified procedures, including the combination
of preoperative gonadotropin-releasing hormone agonist, or
the combination of other operative technologies, such as
uterine vessel occlusion or uterine vessel ligation, combining
laparoscopy and UMLT, and single-port laparoscopic myo-
mectomy, have not been included in this article. In addition,
some important issues, including the use of meta-analysis for
different myomectomy procedures to compare the progress
and/or the clinical impact among the procedures, and the
decision making of the surgical methods (a flow chart:
ultramini-laparotomy in the beginning, then expending the
incisional length to mini-laparotomy due to some technical
problems, and finally a conventional laparotomy) are not
discussed in this article. Furthermore, topics on costs [63],
quality of life, and future reproductive outcomes, were not
included in this article. Finally, we should apologize for the
omission of many valuable articles addressing the topic of
myomectomy, due to limited space.
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